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DNA vaccination can induce speciﬁc CD8+ T cell immune response, but the response level is low in large mammals and human
beings.CoadministrationofanadjuvantcanoptimizeprotectiveimmunityelicitedbyaDNAvaccine.Inthisstudy,weinvestigated
the eﬀect of a synthetic glucohexaose (β-glu6), an analogue of Lentinan basic unit, on speciﬁc CD8+ T cell response induced by
a DNA vaccine encoding HBcAg (pB144) in mice. We found that β-glu6 promoted the recruitment and maturation of dendritic
cells, enhanced the activation of CD8+ and CD4+ T cells and increased the number of speciﬁc CD8+/IFN-γ+ T cells in lymphoid
and nonlymphoid tissues in mice immunized by pB144. Immunization with pB144 and β-glu6 increased the anti-HBc IgG and
IgG2a antibody titer. These results demonstrate that β-glu6 can enhance the virus-speciﬁc CTL and Th1 responses induced by
DNA vaccine, suggesting β-glu6 as a candidate adjuvant in DNA vaccination.
1.Introduction
Sugarsarebioactivecomponentsofmanyplantsandmicroo-
rganisms. Polysaccharides and oligosaccharides of various
origins (fungi, bacteria, plants, etc.) can be recognized by
surface receptors of host cells, in particular macrophages and
dendritic cells, and trigger host innate immune reactions
[1]. Some polysaccharides and oligosaccharides extracted
from plants, such as microgranular formulation of inulin,
can regulate the immune response by acting as adjuvants
to nonspeciﬁcally enhance cellular and humoral immune
responses and activate the innate immunity through the
alternative complement pathway [2].
T h ec u r a t i v ee ﬀects of Ganoderma lucidum and other
mushrooms were recorded in the Compendium of Materia
Medica. Their extracts have been used to prevent and treat
diseases in traditional Chinese medicine. Polysaccharides
and oligosaccharides are the major bioactive molecules in
the extracts [3, 4]. Lentinan, a polysaccharide exacted from
the fungus Lentinus edodes, possesses various biological
activities, such as immune regulation, anti-infection and
anti-tumoral activity [5, 6], and its usage is recorded in
Chinese Pharmacopoeia [7]. Lentinan has potent ability
to activate innate immune eﬀector cells such as mono-
cytes/macrophages and NK cells, and to stimulate cell-
mediated immune response [4, 8]. Kupfahl et al. demon-
strated that Lentinan enhanced the protective CD8+ Tc e l l
response against Listeria monocytogenes in the spleen of
mice [9]. This suggests that Lentinan may be used as an
adjuvant to enhance host’s immune response. However, it is
very hard to extract pure Lentinan from the fruiting body of
Lentinus edodes because the extracted fungal polysaccharides2 Journal of Biomedicine and Biotechnology
and oligosaccharides have some drawbacks, such as the
heterogeneous structures of the saccharides, poor solubility
in water, low purity, and low yield [10]. These disadvantages
limit their applicability in clinical practice.
Many bioactive polysaccharides from fungi and plants
havethecommonstructuralsignatureofβ-(1→6)-branched
β-(1→3) gluco-oligosaccharides [11]. The basic unit β-
(1→6)-branched β-(1→3) glucohexaose in Lentinan plays
a vital role in antitumour activity in mice [12], and
is endowed with the immunostimulatory eﬀects of the
whole polysaccharide. Gu et al. synthetized a β-(1→6)-
branched β-(1→3) glucohexaose analogue containing a α-
(1→3)-linked bond (β-glu6) (patent publication number:
PCT/CN02/00478), and it shows similar eﬀects as Lentinan
on mouse spleen cell proliferation and TNF-α production
[13]. The study by Dong et al. demonstrated administration
of synthetic β-glu6 with hepatitis B surface antigen (HBsAg)
signiﬁcantly increased the antigen-speciﬁc antibody titer and
the number of HBsAg-speciﬁc IL-4-producing T cell in
spleen, and the ratio of anti-HBsAg IgG1/IgG2a was higher
in mice immunized with HBsAg plus β-glu6 than that in
micereceivingHBsAgalone,indicatingashifttowardsaTh2-
biased response [14]. This suggests that β-glu6 can act as an
adjuvanttoenhanceTh2humoralimmuneresponseinduced
by a protein vaccine, but the adjuvant eﬀect of β-glu6 on
speciﬁc CD8+ T cell response needs to be studied.
I naD N Av a c c i n e ,i ti se x p e c t e dt h a tD N Ae n c o d e d
antigens are subjected to intracellular proteasomal degrada-
tion, resulting in peptide fragments that can be presented by
MHC class I antigens to CD8+ T cells, thus mimicking viral
infection [15]. Therefore, DNA vaccines have been exten-
sivelystudiedbothforpreventiveandtherapeuticapproaches
against microbe infections. Coadministration of DNA vac-
cine with adjuvants (such as cytokines, chemokines, CpG
DNA, costimulatory molecules, ligands, etc.) is one of strate-
gies to optimize CD8+ T cells protective immunity [16–18].
Polysaccharides from microorganisms and plants can also be
usedasDNAvaccinesadjuvants.Forexample,Agaricusblazei
Murill extractscontainingagreatquantityofpolysaccharides
have an ability to enhance humoral and cellular immune
responses induced by plasmid DNA encoding HBcAg [19].
In mice, Lentinan was found to increase Env-speciﬁc
type 1 cytokine production and cytotoxic T-lymphocyte
(CTL) activities induced by DNA vaccine, encoding human
immunodeﬁciency virus envelope glycoprotein [20]. Since
the adjuvant eﬀect of β-glu6 on the polarization of Th1/Th2
balance and the induction of antigen-speciﬁc cytotoxic T
lymphocytes upon administration of a DNA vaccine is still
unknown, in the present study, we have investigated eﬀect of
β-glu6 on the antigen speciﬁc CD8+ T cell response induced
by a DNA vaccine encoding HBcAg.
2.MaterialsandMethods
2.1. Plasmid and Reagents. The eukaryotic expression plas-
midpB144waskindlyprovidedbyProf.YuanWang,andwas
constructed by inserting a gene encoding HBcAg N’-end 144
amino acids into a vector (pcDNA3.1, Invitrogen, Carlsbad,
CA, USA) under the control of the cytomegalovirus (CMV)
immediate early promoter. COS-7 cells transiently trans-
fectedwithpB144signiﬁcantlyexpressHBcAgandeﬃciently
secrete it into the cell culture supernatant [21].
2.1.1.PlasmidPuriﬁcation. ThepB144plasmidwasprepared
according to the protocols of QIAGEN-TIP 2500 Plasmid
Mega Kit (Qiagen Corporation, Maryland, USA). A single
colony from a LB/Amp plate was inoculated into LB/Amp
culture medium at 1/1000, and incubated at 37
◦C for 12–
16 hours with vigorous shaking (approx. 300rpm). The
bacterial cells were harvested by centrifugation at 6000xg
for 15 minutes at 4◦C .T h eb a c t e r i a lp e l l e tw a sr e s u s p e n d e d
in Tris·Cl-EDTA buﬀer containing RNase A (100μg/ml)
and lyzed with NaOH (200mM)/SDS (1%). The lysate
was neutralized by the addition of acidic potassium acetate
(3.0M, pH 5.0). The supernatant of lysate was applied
to the QIAGEN-tip. The binding plasmid was eluted in
a high-salt buﬀer, then the DNA was precipitated with
isopropanol. The DNA was dissolved with sterile PBS (pH
7.0). The concentration of plasmid DNA was determined
spectrophotometrically.
2.1.2. Reagents. FITC-CD4 (clone GK1.5), PerCP-CD8a
(clone 53–6.7), APC-IFN-γ (clone XMG1.2), PE-CD11c
(clone HL3), and the Cytoﬁx/Cytoperm Plus kit (with
GolgiPlug) were purchased from BD Biosciences (Franklin
Lakes, NJ, USA). The following reagents were purchased
from Biolegend (San Diego, CA, USA): FITC-CD40 (clone
HM40–3), FITC-CD86 (clone GL-1), FITC-MHC-II (clone
M5/114.15.2), and PE-CD69 (clone H1.2F3). Brefeldin
A was obtained from eBioscience (Boston, MA, USA).
HISTOPAQUE-1083 and Deoxyribonuclease I were from
Sigma-Aldrich (St. Louis, MO, USA). Anti-HBc ELISA kit
and goat antimouse IgG-HRP were purchased from Huamei
Bioengineering Co., Ltd. (Shanghai, China). Bovine anti-
mouse IgG1 and anti-mouse IgG2a were purchased from the
Binding Site Co., Ltd. (Birmingham, UK). Collagenase Type
IV, 2-mercaptoethanol, RPMI-1640 medium, Fetal Bovine
Serum (FBS), L-glutamine, penicillin, and streptomycin
were obtained from GIBCO Invitrogen (Grant Island, NY,
USA). Percoll was purchased from Pharmacia (Uppsala,
Sweden). The peptide MGLKFRQL, representing an H-2Kb-
restricted CTL epitope of the hepatitis B core antigen, was
synthesized and generously provided by Dr. Raﬁ Ahmed
(Emory University, Altanta, GA, USA).
2.2.β-(1→6)-Branchedβ-(1→3)GlucohexaoseAnalogue. β-
glu6 glucohexaose was synthetized by Kong Fanzuo, Ning
Jun, and Gu Jianxin, and identiﬁed with NMR, MS, and
HPLC. 1HNMR (CDCl3,400MHz): δ5.269(d, J3.2Hz, 1H,
H-1α), 4.743(d, J8.0Hz,2H,H-1β), 4.667(c, J8.0Hz, 2H,H-
1β), 4.440(d, J8.0Hz, 2H, H-1β), 4.152–4.081(m, 4H),
3.919–3.256(m, 32 H); 13C NMR(100Hz, D2O):δ102.69
(2 C-1β, JC1-H1 173Hz), 102.6 (3C-1β,JC1-H1 173Hz),
98.92 (1C-1α, JC1-H1 164Hz), 85.34, 84.87,92.90 (C-
3), 81.96, 75.85, 75.76, 75.74, 75.57, 75.54, 75.52,75.45,
75.40, 73.73, 73.34, 73.04, 72.12, 70.98, 70.75, 69.68,69.55,
69.49, 68.86, 68.37, 68.24, 67.78 (C-2,3,4,5,6); ESMS forJournal of Biomedicine and Biotechnology 3
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Figure 1: Eﬀect of the β-glu6 on pB144-induced CD11c+ DC maturation. Mice were injected in the hind leg muscle with β-glu6 (G, 1mg/kg),
pB144 (100μg/mouse), pB144 together with β-glu6 (pB144+G), or PBS. At day 5 after priming (a) and day 5 after boosting (b), spleen
CD11c+ cells coexpressing CD40 (left panels), CD86 (middle panels), or MHC-II (right panels) were measured by ﬂow cytometry. Data are
expressed as mean ± SD of data from 3 mice/group. ∗P<. 05, pB144 +G versus all other groups; #P<. 05, pB144 versus PBS control.
C36H62O31 (992.5):991.4[M-1]+.Thedetailsofthesynthesis
are illustrated in the related patent (publication number:
WO03004507). The purity of the synthetic β-glu6 is more
than 98%, as determined by HPLC. The endotoxin con-
tamination in β-glu6 was under detection level by Limulus
Amoebocyte Lysate (LAL) colorimetric assay (Cambrex;
Walkersville, MD, USA).
2.3. Immunization of Mice with pB144 and β-glu6. Female
inbred C57BL/6 mice (H-2b), aged 6–8 weeks, were pur-
chased from B&K Universal Group Limited (Shanghai,
China), and kept under pathogen-free conditions. Mice
were grouped as described below, each group consisting
of 15 mice. Before immunization, mice were anesthetized
with 0.75% sodium pentobarbital (75mg/kg). One group
of mice was inoculated with pB144 DNA (100μg/mouse)
and synthetic β-glu6 (1mg/kg) in phosphate buﬀered saline
(PBS) into the tibialis anterior muscle of each hind limb,
as previously described [22]. These mice then received daily
intramuscular injections of synthetic β-glu6 (1mg/kg/day
in 100μl PBS) for six days. Another group of mice were
immunized with pB144 DNA alone. Control mice were
administered with the same volumes of PBS. At day 30 after
the ﬁrst immunization with pB144, all mice were boosted
with a second antigen dose, using the same immunization
schedule as in the priming. At days 5, 14, 35, and 40 after
priming, three mice/group were sacriﬁced, and peripheral
blood, spleen, and liver were collected.
2.4. Lymphocyte Preparation. Mice were anesthetized and
sacriﬁced. The peripheral blood was collected from angu-
lar vein, using 4% sodium citrate as an anticoagulant.
PBMC were obtained by density gradient centrifugation
over HISTOPAQUE-1083 (Sigma-Aldrich), washed three
times with RPMI-1640 and counted. Mice spleens were
dissociated on a 200-gauge nylon mesh. Splenocytes were
collected and treated with lysis buﬀer (155mM NH4Cl,
10mM KHCO3,0 . 1m MN a 2EDTA, pH 7.4) to eliminate red
cells,washedandresuspendedinRPMI-1640with10%heat-
inactivated FBS (hereafter referred to as culture medium).
Hepatic lymphocytes were isolated as previously described
[23]. Brieﬂy, the liver was perfused with 5mL RPMI-
1640 (containing 2% FBS, 2mM L-glutamine, 100U/mL
penicillin and streptomycin, resp.) through the portal vein,
then the inferior caval vein was cut and the medium was
allowed to ﬂow until the liver was free of red cells. The liver
was then pressed through 200-gauge nylon mesh, fragments
suspended in RPMI-1640 containing 0.05% collagenase IV
and 0.001% DNase I, and digested at 37
◦Cf o r4 0m i n u t e s .
The liver cell suspension was collected, and mononuclear
cells (MNC) were separated from parenchymal cells by
centrifugation at 500g for 10 minutes. Lymphocyte-rich4 Journal of Biomedicine and Biotechnology
cell pellets were resuspended in 44% Percoll in complete
RPMI-1640 medium, gently overlaid onto 56% Percoll and
centrifuged for 10 minutes at 750g at 4◦C. The pellets were
resuspended in erythrocyte lysing solution (lysis buﬀer with
the addition of 170mM Tris, pH 7.3), washed with RPMI-
1640 and re-suspended in complete RPMI-1640.
2.5. Flow Cytometric Analysis of Surface Markers on Lym-
phocytes. Coexpression of CD11c with CD40, CD86, and
MHC class II on spleen leukocytes was determined by
ﬂow cytometry. Coexpression of CD69 with CD4 and
CD8 on lymphocytes of spleen, liver and peripheral blood
was also assessed. Brieﬂy, cells were stained with relevant
ﬂuorochrome-labelled mAbs for 30 minutes, washed with
FACScan buﬀer (PBS containing 2% FBS and 0.1% sodium
azide), then ﬁxed with 4% paraformaldehyde. Fluorescence
proﬁles were generated on a FACScan ﬂow cytometer (BD
Biosciences). For each sample, 100,000 cells were collected
and histogram and density plots were produced by the
CellQuest software package.
2.6. Detection of IFN-γ Producing T Cells by Intracellular
Cytokine Staining. At day 5, 14, and 40 after primary
immunization, IFN-γ production was detected by intracel-
lular staining. Spleen cells, PBMC, and hepatic lymphocytes
were plated separately (1 × 106 cells/well) in a 96-well
plate (Corning Costar; Cambridge, MA) in a ﬁnal volume
of 200μl. Cells were stimulated with a speciﬁc peptide
correspondingtoaKb-restrictedCTLepitopeofthehepatitis
B core antigen (ﬁnal concentration 1μg/mL) for 5 hours at
37
◦C in moist atmosphere with 5% CO2, in the presence
of Brefeldin A (ﬁnal concentration 2μg/mL). Cells were
then stained with PerCP-conjugated anti-CD8a mAb for 30
minutes at 4◦C, washed with FACS buﬀer (2% FBS, 0.1%
sodium azide in PBS), treated with Cytoﬁx/Cytoperm for
20 minutes, and washed with Perm/Wash Buﬀer (both from
BD Biosciences). Cells were subsequently stained with APC-
conjugated anti-mouse IFN-γ mAb for 30 minutes at 4◦C,
washed with Perm/Wash Buﬀer and FACS buﬀer, and ﬁxed
with4%(w/v)paraformaldehyde.Sampledatawereacquired
using a FACSCalibur ﬂow cytometer (BD Biosciences).
2.7. Detection of Anti-HBc Antibodies. Blood was collected
from the retroorbital plexus of mice after 4 weeks from
the primary immunization and 2 weeks from boost, and
serum were obtained. The titer of anti-HBc antibodies was
measuredbyELISA(anti-HBcELISAkit;DiagnosticReagent
Center of Shanghai Municipal Infectious Diseases Hospital,
Shanghai, China). Serum was serially diluted in PBS with
5% nonfat milk (starting from 1:100) and incubated in
microtitre plates precoated with HBcAg for 1 hour at 37
◦C.
Plates were then washed and further incubated (1 hour at
37
◦C) with 100μL of HRP-conjugated goat anti-mouse IgG,
bovine anti-mouse IgG1, or bovine anti-mouse IgG2a. After
extensive washing, 50μl of substrate were added to each well
and incubated for 15 minutes at 37
◦C. The plates were read
at 450nm (reference wavelength 630nm) with a BenchMark
ELISA reader (Bio-Rad Laboratories, Hercules, CA, USA).
Thecut-oﬀlinediscriminatingbetweenpositiveandnegative
antibody detection was set as 0.20 (OD 450/630). The
endpoint titer of anti-HBc antibodies is reported as the
reciprocal of the highest dilution at which the OD 450/630
reading is above 0.20.
2.8. Statistical Analysis. Data are presented as mean ± SD
of values obtained from replicate mice within a single
representative experiment. Each experiment was repeated at
least three times with similar results. Results were analyzed
with SPSS software and compared by ANOVA and the post-
hocanalysis.AP-valueof<. 05wasconsideredasstatistically
signiﬁcant.
3. Results
3.1. Eﬀect of β-glu6 on PB144-Induced Maturation of CD11c+
Dendritic Cells in the Spleen. Activated dendritic cells (DC)
have a strong antigen-presenting capacity. The eﬀect of
β-glu6 on pB144-induced activation of DC in mice was
studied. In the spleen of mice immunized intramuscularly
with pB144 plus β-glu6, the number of CD11c+ cells
coexpressingCD40,CD86,orMHC-IIwasexaminedbyﬂow
cytometry. Compared with the mice immunized with pB144
alone, the populations of mature DC (CD11c+/CD40+,
CD11c+/CD86+, and CD11c+/MHC-II+)i nm i c ei m m u -
nized by pB144 with β-glu6 at day 5 after priming were
increased 1.8-, 4.4-, and 3.2-fold, respectively, as shown in
Figure 1(a).
Compared to cells in na¨ ıve animals, at day 5 after boost-
ing, CD11c+/CD40+, CD11c+CD86+, and CD11c+/MHC-
II-+ DC increased about 3–3.5 times in the spleen of mice
immunized with pB144 alone (from 1.3 × 106,1 .1 × 106,
and 2.9 × 106 in na¨ ıve mice to 4.9 × 106,3 .1 × 106,a n d
8.7×106 inpB144immunizedmice),andabout4.5–5.6times
in the spleen of mice receiving pB144 plus β-glu6 (7.3 × 106,
4.9×106,a n d1 3 .6×106,r e s p . )( Figure 1(b)). No statistically
signiﬁcant diﬀerence was observed between na¨ ıve mice and
mice receiving β-glu6 alone intramuscularly.
3.2. Eﬀect of β-glu6 on PB144-Induced Recruitment and
Activation of CD4+ and CD8+ TC e l l s . The recruitment and
activation of CD4+ T cells in the spleen of mice immunized
by pB144 with or without β-glu6 were evaluated. At day
5 after priming, compared to the mice immunized with
pB144 alone, the percentage of CD4+ T cells in the mice
immunized by pB144 with β-glu6 was higher in the spleen
(from21.5%to27.3%)(Figure 2(a)).Atday5afterboosting,
the percentage of CD4+ T cells in the mice immunized by
pB144 with β-glu6 increased from 24.8% to 29.3% in the
spleen (Figure 2(a)). Both at day 5 after priming and at day
5 after boosting, the number of activated CD4+/CD69+ T
cells in the spleens of mice immunized by pB144 with β-
glu6 was about 1.7-fold higher than that in mice immunized
with pB144 alone (Figure 2(b)). The recruitment of CD4+ T
cells in the liver and peripheral blood of mice immunized
by pB144 with β-glu6 was of no signiﬁcant diﬀerence from
that in the mice immunized with pB144 alone, shown inJournal of Biomedicine and Biotechnology 5
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Figure 2: Eﬀect of β-glu6 on pB144-induced recruitment and activation of CD4+ T cells in the spleen. Mice were immunized with β-glu6 (G),
pB144, pB144+G, or PBS as described in Section 2. Five days after priming and ﬁve days after boosting, the percentage of CD4+ Tc e l l s( a )
and the number of CD4+/CD69+ T cells (b) in the spleen were evaluated. Data are expressed as mean of 3 mice/group. ∗P<. 05, pB144+G
versus pB144 alone.
the Supplementary Figure 1 (see in supplementary Material
available online at doi:10.1155/2010/645213).
The recruitment and activation of CD8+ T cells in the
spleen of mice immunized by pB144 with or without β-glu6
were evaluated. At day 5 after priming, upon treatment with
β-glu6, the number of CD8+ T cells in the spleen of pB144-
immunized mice was increased from 17.9×106 to 23.9×106
(Figure 3(a)). At day 5 after boosting, β-glu6 enhanced the
pB144-induced recruitment of CD8+ T cells into the spleen
by 1.7-fold (from 18.9 × 106 to 31.7 × 106 cells/spleen,
P<. 05) (Figure 3(a)). At day 5 after priming, a higher
number of CD8+ T cells in splenocytes were activated by
administration of pB144 with β-glu6, as compared to pB144
alone, judged by the expression of the CD69 as an activation
marker(from3.8×106 to5.9×106 CD8+/CD69+ cells/spleen,
P<. 05), while activated CD8+/CD69+ T cells were increased
to 8.3 × 106/spleen (P<. 05 versus pB144 alone), at day 5
after boosting (Figure 3(b)). The number of CD8+ Tc e l l si n
the liver and peripheral blood was not statistically diﬀerent
among groups (Supplementary Figure 2).
3.3. Eﬀect of β-glu6 on PB144-Induced Antigen Speciﬁc
CD8+/IFN-γ+ TC e l l s .The eﬀect of β-glu6 on antigen-
speciﬁc CD8+/IFN-γ+ T cells in the mice immunized with
pB144 was evaluated by intracellular cytokine staining, stim-
ulated with the peptide MGLKFRQL, an H-2Kb-restricted6 Journal of Biomedicine and Biotechnology
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Figure 3: Eﬀect of β-glu6 on pB144-induced recruitment and activation of CD8+ T cells in the spleen. Mice were immunized with β-glu6 (G),
pB144, pB144+G, or PBS, as described in Section 2. Five days after priming and ﬁve days after boosting, the number of CD8+ Tc e l l s( a )a n d
CD8+/CD69+ T cells (b) in the spleen were evaluated. Data are expressed as mean ± SD of 3 mice/group. ∗P<. 05, pB144+G versus pB144
alone.
CTL epitope of the hepatitis B core antigen. At day 5 and
14 after priming, β-glu6 did not increase the number of
CD8+/IFN-γ+ T cells in the spleen (Figure 4). However, at
day 10 after boosting, the number of CD8+/IFN-γ+ Tc e l l s
was 1.5-fold higher in splenocytes from mice immunized by
pB144 with β-glu6, as compared to mice immunized with
pB144 alone. β-glu6 increased the percentage of CD8+/IFN-
γ+ T cells induced by pB144 in the liver (0.54 ± 0.08%),
PBMC (0.74 ± 0.17%), and the spleen (1.5 ± 0.3%), as
compared with that in mice immunized with pB144 alone
(Figure 5).
3.4.β-glu6EnhancedthePB144-InducedAntibodyProduction.
The eﬀect of β-glu6 on anti-HBc antibody response induced
by the DNA vaccine was evaluated by ELISA. Anti-HBc
antibodies (IgG)in sera fromimmunized mice weredetected
at 4 weeks after priming and 2 weeks after boosting. At
4 weeks after priming, anti-HBcAg antibody titers in mice
immunized with pB144 alone (1:900) were lower than that
in mice receiving pB144 plus β-glu6 (1:2700) (Table 1). No
anti-HBcAg antibodies were detected in the serum of control
mice injected with PBS or β-glu6 alone. At 2 weeks after
boosting, anti-HBc IgG was higher in mice immunized by
pB144 with β-glu6 (1:24,300) than that in mice immunized
with pB144 alone (1: 8100).
The IgG subclasses (IgG1 and IgG2a) of anti-HBc
antibody were analyzed. At week 4 after priming, only low
level of IgG2a was detected in mice immunized by pB144
with β-glu6. At week 2 after boosting, the mean titer of anti-
HBc IgG2a was 1:4500 in the mice immunized by pB144
with β-glu6, and 1:3600 (mean) in mice receiving pB144
alone (Table 1). Anti-HBc IgG1 was under detection level in
the all groups, even after boosting.
4. Discussion
Virus-speciﬁc CD8+ T cells response plays an important role
intheprocessofviralclearance.HerpesSimplexVirus(HSV)
began to be cleared from all sites about 5 days after infection
when HSV glycoprotein B-speciﬁc CD8+ T cells ﬁrst appear
within infected tissues [24]. The failure of inducing a virus-
speciﬁcCD8+ TcellresponsecontributestothedevelopmentJournal of Biomedicine and Biotechnology 7
Table 1: Eﬀect of β-glu6 on pB144-induced antibody production∗.
Immunogens
Anti-HBcAg antibody titer (Log2± SD)∗∗
Week 4 after priming Week 2 after boosting
IgG IgG1 IgG2a IgG IgG1 IgG2a
G N.D.∗∗∗ N.D. N.D. N.D. N.D. N.D.
pB144 9.81 ±0.21 N.D. N.D. 12.98 ±0.18 N.D. 11.81 ±0.55
pB144+G 11.40 ±
0.09∗∗∗∗ N.D. 6.90 ±0.49 14.57±0.50∗∗∗∗ N.D. 12.13 ±0.6
PBS N.D. N.D. N.D. N.D. N.D. N.D.
∗The sera from immunized mice were collected 4 weeks after priming and 2 weeks after boosting. Anti-HBcAg IgG, IgG1, and IgG2a were analyzed by ELISA.
The initial dilution of each serum from immunized mouse was 1:100 and followed with serial of three-fold dilution for anti-HBc IgG detection, and two-fold
dilution for anti-HBc IgG1, IgG2a analysis.
∗∗The well with an absorbance OD450 ≥0.20 (the blank well, ∼0.020) was scored as positive. The anti-HBc antibody titers are expressed as the reciprocal of
the highest dilution showing a positive reaction and calculated as the mean ± standard deviation (SD) of Log2 f o re a c hg r o u p( 6m i c e / g r o u p ).
∗∗∗N.D. indicates that anti-HBc antibody in the sera of the mice is under detection level.
∗∗∗∗P<. 05, pB144 +G versus pB144 alone.
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Figure 4: Eﬀect of β-glu6 on the CD8+/IFN-γ+T cells induced by
pB144 in the spleen. Mice were immunized by pB144 with β-glu6,
and boosted at day 30 after priming. At day 5 (left) and 14 (middle)
after priming, and day 10 after boosting (right), splenocytes were
isolated and cultured for 5 hours in the absence or in the presence
of a speciﬁc peptide corresponding to K
b-restricted CTL epitope of
HBcAg. Cells were then double-stained with PerCP-anti-CD8a and
APC-anti-IFN-γ antibodies andanalyzed cytoﬂuorimetrically. Data
expressedasmean ±SDof3mice/group. ∗P<. 05,pB144+Gversus
pB144 alone.
of pulmonary eosinophilia and disease augmentation in
formalin-inactivated respiratory syncytial virus vaccine vac-
cinated individuals [25]. DNA immunization has the ability
to induce a strong speciﬁc CD8+ T cell response against a
variety of infectious diseases [26–28].
However, clinical applications of DNA vaccines are lim-
ited by their low immunogenicity. Therefore, it is imperative
to develop eﬀective adjuvants for improving protective
response in DNA vaccination. Adjuvants have been proven
to optimize CD8+ T cells response induced by DNA vaccine.
Forexamples,cytokineplasmid-deliveredIL-15enhancesthe
longevity of CD8+ T cells induced by pB144 DNA vaccine
[18]; soluble CD40L, a member of the tumor necrosis factor
superfamily, augments CD8+ T cell responses induced by
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Figure 5: Eﬀect of β-glu6 on the CD8+/IFN-γ+ T cells induced by
pB144 in diﬀerent organs. Mice were immunized with pB144 and
treated with β-glu6, and boosted at day 30. Ten days after boosting,
the liver lymphocytes, PBMC, and splenocytes were isolated and
cultured for 5 hours in the absence or in the presence of a speciﬁc
peptide corresponding to K
b-restricted CTL epitope of HBcAg.
Cells were then double-stained with PE-anti-CD8a and APC-
anti-IFN-γ antibodies and analyzed cytoﬂuorometrically. Data are
expressedasmean ±SDof3mice/group. ∗P<. 05,pB144+Gversus
pB144 alone.
human immunodeﬁciency virus DNA vaccines [16]. Some
polysaccharides extracted from plants or microorganisms
possess ability to improve the protective potential of a DNA
vaccine against experimental infection [19, 29].
β-glu6 is a synthetic glucohexaose containing a structure
of β-(1→6)-branched β-(1→3) with an α-(1→3)-linked
bond, that is an analogue of Lentinan basic unit. Lentinan
was extracted from Lentinus edodes being recorded in
Compendium of Materia Medica for the treatment and
prevention of diseases in traditional Chinese medicine.
Lentinan can strengthen the cell-mediated immune response
[30, 31] and activate some innate immune eﬀector cells
such as mononuclear macrophages and NK cells [11].
Administration of Lentinan before infection can mobilize
host defence and reduce mycobacterial infection [32].
The β-(1→6)-branched β-(1→3) glucohexaose is a basic
unit of Lentinan, endowed with potent anticarcinoma8 Journal of Biomedicine and Biotechnology
activity. β-glu6, synthetic glucohexaose analogue, has
stimulatory eﬀects on mouse spleen cells (cell proliferation,
TNF-α production), which is similar to Lentinan [12, 13].
Furthermore, β-glu6 has the advantages over Lentinan, such
as possessing a deﬁned structure, higher purity (>98% by
HPLC), and availability.
Based on the study of β-glu6 as adjuvant enhancing
eﬀectivity of protein vaccine (Hepatitis B surface antigen)
[14], we further investigated the adjuvant eﬀect of β-glu6
on antigen-speciﬁc CD8+ T cell response induced by DNA
vaccineencodingHBcAg(pB144)thatcanbeusedasantigen
candidate of DNA vaccine against HBV. We found β-glu6
possessabilitytoenhancethematurationofDCs,therecruit-
ment and activation of T cells, and to increase the number of
antigen-speciﬁc CD8+/IFN-γ+ T cells induced by pB144.
DCs function as both antigen-presenting cells and
antigen-producing cells in DNA vaccine immunization.
Thus, triggering DC activation can improve the eﬃcacy
of genetic vaccines [33]. Immunization of HIV-1 envelope
(env) DNA vaccine alone recruited few DCs to the injec-
tion site and elicited low-frequency, Env-speciﬁc immune
responses in mice [34]. As an endogenous ligand, polysac-
charide degradation products of the extracellular matrix
produced during inﬂammation may activate DCs via TLR4
[35]. In the previous study, it showed administration of β-
glu6 (i.p.) alone has eﬀect on DC recruitment and matura-
tion in the spleen [14]. Maturation of bone marrow-derived
dendritic cell (MDC) induced by HBsAg was enhanced
with β-glu6 treatment, and in mixed lymphocyte reaction
with MDC the proliferation of T cells was increased with
the treatment of β-glu6 and HBsAg (unpublished data).
In the present study, β-glu6 was able to enhance the DC
maturation and migration to the spleen induced by DNA
vaccines. We investigated the eﬀect of anti-TLR2 and anti-
TLR4 on β-glu6 immune activity, and found that the
antibody against to TLR2 or TLR4 inhibited the activities
of β-glu6 inducing TNF-α s e c r e t i o ni nam o u s em a c r o p h a g e
cell line, RAW264.7, suggesting that β-glu6 may activate
innate immune cells via TLR2 or TLR4 signal pathway,
t h o u g hi tn e e d st ob ec o n ﬁ r m e di nv i v o .D Cm a t u r a t i o n
may be related with β-glu6 enhancing the HBcAg-speciﬁc
CD8+ T cell response induced by DNA vaccine. Steﬀen
Jung et al. observed that DC-depleted mice fail to mount
CTL responses to infection with the intracellular bacterium
Listeria monocytogenes and the rodent malaria parasite
Plasmodium yoelii [36], suggesting that DC maturation play
ar o l ei ns p e c i ﬁ cC D 8 + T cell activation.
Antigen-speciﬁc CD8+ and CD4+ T cells play a vital
role in control of viral infection. They can remove infected
target cells through cytotoxic or noncytotoxic function,
such as producing IFN-γ and other Th1 cytokines [37].
Christine Heuﬂer’ et al. found DC produced bioactive IL-
12 upon antigen-speciﬁc interaction with T cells without any
other stimuli, and DC-derived IL-12 was critical for optimal
proliferation and IFN-γ production by activated Thl blasts
[38]. The enhancement of DC maturation, migration, and
the antigen presentation increased the number of antigen-
speciﬁc CD8+/IFN-γ+T cells in DNA vaccine-immunized
mice [39]. Booster injections with mature DCs raised CD8+
Tc e l lr e s p o n s ei nh u m a n s[ 40]. In the mice immunized
by pB144 with β-glu6, the number of HBcAg-speciﬁc
CD8+/IFN-γ+ T cells in lymphoid tissues (the spleen) and
nonlymphoid tissue (the liver), were higher than that in
the mice vaccinated by pB144 alone, suggesting that β-
glu6 can amplify speciﬁc Th1 immune response induced
by the DNA vaccine. With Lentinan being injected into
mice intraperitoneally, the macrophage glutathione redox
status and capability to produce IL-12 were improved, thus
orienting toward type-1 immunity [41]. The eﬀect of β-
glu6 on the IFN-γ, IL-4 and DC-derived IL-12 production
induced by pB144 needs to be further investigated.
In the present study, we found that β-glu6 increased
the recruitment of CD4+and CD8+ T cells to the spleen,
which was induced by pB144. With recruitment of antigen—
nonspeciﬁc CD4+ and CD8+ T cells to lymphoid tissue,
T cell-derived cytokines may help antigen-speciﬁc T cells
augmentation.
When the antigen is endogenously produced upon
intramuscular DNA vaccination, β-glu6 improved anti-HBc
antibody production, in mice which the major IgG subclass
of anti-HBc antibody was IgG2a and IgG1 were detected
scarcely, and ampliﬁed the HBcAg-speciﬁc CD8+ Tc e l l
response induced by DNA vaccine, that indicates a bias
towards a Th1 immune response. In the previous study, β-
glu6 improved anti-HBsAg IgG1 antibody production and
the number of HBsAg-speciﬁc IL-4-producing T cells in
spleen in mice immunized with HBsAg protein vaccine [14],
indicating that β- g l u 6c a na c ta sa na d j u v a n tf o rap r o t e i n
vaccine shifting towards a Th2-biased response. The roles
of route of antigen entry, the physical form of antigen, the
type of adjuvant and the dose of antigen in controlling
the type of Th-cell diﬀerentiation have been reported [42].
Apparently, β-glu6 can amplify diﬀerent types of responses,
depending on the type of the vaccine utilized. Recent work
suggests that dendritic cell subsets contribute signiﬁcant
polarizing inﬂuences on T helper diﬀerentiation, but how
this comes about is less clear. Mosmann and Coﬀman
indicated a single APC type may inﬂuence the Th1/Th2
ratio by providing diﬀerent accessory signals to Th cells,
depending on the physical nature of the antigen encountered
[33, 43]. The physical type of vaccine and DC distinct roles
in immunization may contribute to β-glu6 skewing Th1/Th2
immune response induced by vaccine that warrant to study.
Because mice is a species already known to respond very
well to DNA immunization, the eﬀect of β-glu6 has yet
to be proved in another animal species refractory to DNA
immunization, like nonhuman primates. Since Lentinan is
recorded in Chinese Pharmacopoeia as an immunopotentia-
tor, the plasticity of the adjuvant eﬀects displayed by β-glu6,
which contains the basic bioactive unit of Lentinan, makes it
a suitable candidate adjuvant for diﬀerent types of vaccines,
providing its potential clinical application.
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